Abstract
No public abstract is available from the verified source records.
Sanna Laaksonen, Igor Odintsov, Lynette Marie Sholl
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies
10.4161/cbt.11.7.14948 · 2011
Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition
10.1016/j.jbc.2023.105492 · 2024
Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer
10.1002/2056-4538.70012 · 2025
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
10.1126/science.aad5214 · 2016
Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data
10.1016/j.esmoop.2025.104535 · 2025
Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma
10.1111/his.14324 · 2021
MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma
10.1038/s41379-019-0310-0 · 2020
Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency
10.1002/cam4.4971 · 2023
Confidence 95%
datacite
Confidence 0%
Deficiency of MTAP Is Frequent and Mostly Homogeneous in Pancreatic Ductal Adenocarcinomas
10.3390/cancers17071205 · 2025
MTAP loss: a possible therapeutic approach for glioblastoma
10.1186/s12967-022-03823-8 · 2022
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer
10.1016/j.euo.2021.10.006 · 2023
MTAP as an emerging biomarker in thoracic malignancies
10.1016/j.lungcan.2024.107963 · 2024
Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC)
10.1038/sj.onc.1202205 · 1998
Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue
10.1016/j.gendis.2022.04.001 · 2023
Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers
10.1158/2159-8290.cd-23-0951 · 2023
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration
10.1016/j.annonc.2024.08.2339 · 2024
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007
10.1200/jco.2025.43.16_suppl.3011 · 2025
Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma
10.1016/j.modpat.2023.100420 · 2024
OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine
2015
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers
10.1136/jcp-2023-209341 · 2025
Analysis of TERT mRNA Levels and Clinicopathological Features in Patients with Peritoneal Mesothelioma
2025
New driver mutations in non-small-cell lung cancer
10.1016/s1470-2045(10)70087-5 · 2011
10.1007/978-1-4614-7645-0
10.1007/978-1-4614-7645-0
Clinical Implementation of Matched Tumor/Germline Sequencing Improves Accuracy of Tumor Genomic Profiling and Therapeutic Recommendations
10.1016/j.jmoldx.2025.06.005 · 2025
Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC
10.1016/j.jtho.2025.11.010 · 2026
MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC
10.1016/j.jtho.2025.08.014 · 2026
Lung Cancer in Non-Smokers
2020
Lung cancer in never-smokers
10.1183/09031936.00046915 · 2015
Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma
10.1038/s41379-022-01081-z · 2022
Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma
10.1038/s41379-019-0309-6 · 2020
Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia
10.1016/j.lungcan.2019.02.004 · 2019
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry
10.1016/j.lungcan.2016.12.017 · 2017
Malignant mesothelioma in situ: morphologic features and clinical outcome
10.1038/s41379-019-0347-0 · 2020
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
10.1016/j.annonc.2026.03.001 · 2026
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
10.1038/s41467-023-41670-3 · 2023
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
10.1038/s41467-017-02584-z · 2018
Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma
10.1016/j.lungcan.2008.04.019 · 2009
MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients
10.1016/j.ejso.2014.04.017 · 2014
MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab
10.1038/s41598-020-57812-2 · 2020
MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review
10.1093/jnen/nlaf033 · 2025
Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips
10.4132/jptm.2016.08.08 · doi-reference
Genomic landscape of deletions and association with alterations in NSCLC
10.1200/jco.2024.42.16_suppl.8599 · doi-reference
Liquid biopsy detection of gene Copy Number (CN) losses including existing and emerging clinical targets
10.1016/j.jlb.2024.100221 · doi-reference
Liquid Biopsy: General Concepts
10.1159/000499337 · doi-reference
Epigenetic Modifications as Novel Biomarkers for Diagnosis, Prognosis, and Therapeutic Targeting in Thyroid, Pancreas, and Lung Neuroendocrine Tumors
10.3390/jcm14082622 · doi-reference
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma
10.1016/s0002-9440(10)63695-4 · doi-reference
Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma
10.1093/carcin/bgi201 · doi-reference